top of page
Browse by category
Search
FDA expands Ethicon’s Linx Reflux Management System to include patients with Barrett’s esophagus experiencing GERD
The FDA has approved a label update to expand the availability of Ethicon’s Linx Reflux Management System to include patients with...
ANSM suspends Allurion gastric balloons in France
The Agence nationale de sécurité du médicament et des produits de santé (ANSM, National Medicines Safety Agency) in France has suspended...
FDA grants Breakthrough Device Designation for Fractyl’s Revita in weight maintenance for people with obesity who discontinue GLP-1s
The FDA has granted Breakthrough Device Designation (BDD) for Fractyl Health’s Revita System for use in the maintenance of weight loss...
Phenomix launches personalised obesity care genetic testing available to women in with Hello Alpha partnership
Phenomix Sciences has entered a partnership with Hello Alpha, a virtual primary care platform, to enable women to take control of their...
ReShape Lifesciences sells obesity devices to Biorad Medisys
ReShape has entered into an asset purchase agreement with Biorad Medisys, which is party to a previously disclosed exclusive license...
iHerb launches new GLP-1 support products designed to combat common side effects from rapid weight loss
iHerb has launched three new supplements specifically designed to support individuals using semaglutide (GLP-1 agonists) by addressing...
WHO issues warning on falsified medicines as Lilly warns patients about counterfeit and compounded medicines
The World Health Organization (WHO) has issued a medical product alert on falsified semaglutides, the type of medicines that are used for...
Unjury Protein launches Protect & Restore Advanced Protein+ to reduce side effects of GLP-1 RAs
Unjury Protein has launched its Protect & Restore Advanced Protein+ - the first clinically supported medical food and co-therapy for...
Aphaia Pharma completes enrolment of phase 2 trial in individuals with obesity
Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore endogenous endocrine balance for the...
Scottish Medicines Consortium accepts tirzepatide (Mounjaro) for obesity in eligible adults
The Scottish Medicines Consortium (SMC) has accepted Eli Lilly and Company’s tirzepatide (Mounjaro) for restricted use within NHS...
Browse by tag
bottom of page